Strategy and validation of a nonclinical generic plug-and-play antidrug antibody method for human monoclonal antibody biotherapeutics


Monoclonal antibody production

Polsky R, Gunn G, Reese KJ, et al. | Bioanalysis, 16(05), 277-287, (2024) Keywords: • ADA • antidrug antibody • biotherapeutic • generic • immunoassay • immunogenicity assay • mAb • nonclinical • plug-and-play The measurement of antidrug antibodies (ADA) in nonclinical studies provides limited value because the formation and incidence of nonclinical ADA does not translate to clinical experience. The formation and presence of ADA in nonclinical species can, however, correlate to reduced drug exposure and safety observations including vasculitis and immune complex disease. Generic ADA methods for humanized monoclonal antibody biotherapeutics mitigate the need to develop bespoke ADA methods during nonclinical drug development. A drug-tolerant, sensitive, generic ADA immunoassay has been developed and validated for...

To view this content, please register now for access

It's completely free